Skip to content

Lucid Diagnostics LUCD Amortization Of Common Stock Payments

Amortization Of Common Stock Payments at other companies

Digital Realty logo
Digital RealtyDLR
$24.01M+60.8%
U.S. Gold Corp. logo
U.S. Gold Corp.USAU
$15K
Digital Realty logo
Digital RealtyDLR
$24.01M+60.8%
First Seacoast Bancorp logo
First Seacoast BancorpFSEA
$237K+1.7%
Digital Realty logo
Digital RealtyDLR
$26.4M+53.0%
TTR
Turn Therapeutics Inc. Common StockTTRX
$250K

Other financials

Income statement

See full
Revenue$1.3M+51.7%
Gross profit-$369.0K+49.0%
Operating income-$12.1M+3.0%
Net income-$13.9M+48.3%
EPS (diluted)-$0.10+60.0%

Balance sheet

See full
Cash & equivalents$27.9M+10.6%
Total debt$1.6M-35.1%
Total equity$4.0M+174%
Total assets$34.1M+3.9%

Cash flow

See full
Operating cash flow-$12.1M+2.9%
CapEx$215.0K+131%
Free cash flow-$12.3M+1.9%

Valuation

See full
Market cap$204.13M+58.5%
Enterprise value$177.85M+78.0%
P/S39.8×+10.2×

Profitability

See full
Gross margin-66.8%
Operating margin-959.6%-133pp
Net margin-876.7%-254pp
FCF margin-1,099.6%

Returns & leverage

See full
Return on equity-710.6%
Debt / equity0.4×
Current ratio1.1×+0.3×

Where this comes from

Reported directly by Lucid Diagnostics in its filing.

Tagged under the XBRL concept lucd:AmortizationOfCommonStockPayments.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's amortization of common stock payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lucid Diagnostics's amortization of common stock payments?
Lucid Diagnostics (LUCD) reported amortization of common stock payments of $29K in Q1 2026.
How has Lucid Diagnostics's amortization of common stock payments changed year-over-year?
Lucid Diagnostics's amortization of common stock payments decreased by 60.8% year-over-year, from $74K to $29K.
What does amortization of common stock payments mean?
This metric captures the periodic expense recognized for equity-based compensation or payments made in the form of common stock. It represents the systematic allocation of the fair value of equity instruments granted to employees or service providers over the requisite service period. Tracking this helps investors assess the non-cash impact of stock-based compensation on the company's profitability and the potential for shareholder dilution.